PreciPoint Group GmbH, a Freising, Germany-based medtech startup, closed its EUR10M Series A financing round.
Backers included bm-t beteiligungsmanagement thüringen gmbh (bm|t) and a new family office.
The company intends to use the funds for:
- expansion of the international commercialization of the first IVD medical product,
- the market entry in the USA, and
- further technological development.
Led by Nicolas Weiss, CEO, PreciPoint specializes in the development, production and marketing of digitization solutions and photonics systems. Already available are the M8, O8 as well as FRITZ. These are fully motorized transmitted light microscopes, which produce high-resolution images and can be handled remotely. Additionally, the company offers software applications to visualize process and analyze, as well as the virtual microscopy platform PreciCloud to store and share the images.
PreciPoint will launch the iO:M8 ROSE solution to customers in 2022, a globally solution for the digitization of intraoperative assessments during cancer surgeries.